Univariable and multivariable association of BMI category change with TB treatment mortality.

*<p>p-value of likelihood ratio test.</p>#<p>Adjusted for sex, age group, project, ART as time dependent variable and BMI category at TB treatment start.</p>##<p>Adjusted for sex, age group, project, ART as time dependent variable, BMI category and CD4 category at TB treatment start.</p><p>CI = confidence interval. HR = hazard ratio. TB = tuberculosis. ART = antiretroviral therapy. BMI = body mass index.</p

Flow diagram showing sample construction.

<p>Flow diagram showing sample construction.</p

Characteristics of final TB patient sample at TB treatment start, ART exposure and TB treatment duration.

*<p>2 months of rifampicin (R), isoniazid (H), pyrazinamide (Z), ethambutol (E), followed by 4 months of rifampicin (R) and isoniazid (H). Patients not on this recommended regimen were either receiving different treatment due to side effects, or were receiving streptomycin instead of ethambutol with a diagnosis of extrapulmonary meningitis.</p><p>IQR = interquartile range. ART = antiretroviral therapy. BMI = body mass index. CPT = cotrimoxazole preventive therapy. TB = tuberculosis.</p

Intervals for measurement of weight and CD4 count at TB treatment start and 1 month after TB treatment start.

<p>Intervals for measurement of weight and CD4 count at TB treatment start and 1 month after TB treatment start.</p

Association of smear-negative and extrapulmonary TB patient samples with basic demographic and epidemiologic variables.

<p>ART = antiretroviral therapy. TB = tuberculosis.</p><p>A total of 81 deaths and 126 unfavorable outcomes were recorded among the 605 smear negative TB patients, compared to 69 deaths and 120 unfavorable outcomes among the sample of 485 extrapulmonary individuals. The log rank test for equality of survivor functions shows that the data are consistent with no difference in survivor functions for mortality or unfavorable treatment outcomes between the smear-negative and extrapulmonary TB patient samples (p = 0.908 and 0.451, respectively).</p

Baseline proportions and association of factors with default by univariate analysis.

<p>BMI = body-mass index. MDR = multidrug-resistant. Cat I = category I treatment. Cat II = category II treatment. XDR = extensively drug-resistant.</p

Factors associated with default identified by multivariate analysis.

<p>OR = odds ratio. XDR = extensively drug-resistant. Cat II = category II treatment.</p

Disease specific Incidence of WHO stage 4 conditions in months 0–3 following ART initiation by age.

<p>Disease specific Incidence of WHO stage 4 conditions in months 0–3 following ART initiation by age.</p

Disease specific Incidence of WHO stage 3 conditions in months 0–3 following ART initiation by age.

<p>Disease specific Incidence of WHO stage 3 conditions in months 0–3 following ART initiation by age.</p

Disease specific incidence over 36 months for selected WHO Stage 3 conditions.

*<p>n = the number of patients who were followed up for the entire time period indicated.</p